Lighting the way to host-directed immunotherapeutics

Sarah van Tol; Adam Hage; Ricardo Rajsbaum

doi:10.1016/j.chembiol.2022.06.009

Lighting the way to host-directed immunotherapeutics

Cell Chem Biol. 2022 Jul 21;29(7):1067-1070. doi: 10.1016/j.chembiol.2022.06.009.

Authors

Sarah van Tol¹, Adam Hage², Ricardo Rajsbaum³

Affiliations

¹ Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: savantol@utmb.edu.
² Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: arhage@utmb.edu.
³ Center for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, USA. Electronic address: ricardo.rajsbaum@rutgers.edu.

Abstract

Developing broad-spectrum, host-directed antiviral therapeutics can be adapted to combat emerging viruses. In this issue of Cell Chemical Biology, Maarifi and colleagues implement a Nano luciferase reporter-based protein complementation assay to screen for small molecules and identify Gilteritinib, which enhances interferon induction and antagonizes virus replication.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Antiviral Agents* / pharmacology
Antiviral Agents* / therapeutic use
Immunotherapy
Virus Replication*

Substances

Antiviral Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding